|
GB1039113A
(en)
|
1964-08-06 |
1966-08-17 |
Ucb Sa |
New n-substituted lactams
|
|
GB1309692A
(en)
|
1970-02-13 |
1973-03-14 |
Ucb Sa |
N-substituted lactams
|
|
IT1045043B
(it)
*
|
1975-08-13 |
1980-04-21 |
Isf Spa |
Derivati pirrolidinici
|
|
IT1075280B
(it)
*
|
1977-02-11 |
1985-04-22 |
Isf Spa |
Procedimento per la preparazione di derivati pirrolidinici
|
|
BE864269A
(fr)
*
|
1977-03-03 |
1978-06-16 |
Parke Davis & Co |
Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
|
|
EP0005689B1
(fr)
*
|
1978-05-08 |
1981-03-18 |
U C B, S.A. |
Nouveaux acides lactame-N-acétiques et leurs amides, leurs procédés de préparation et compositions thérapeutiques
|
|
US4654370A
(en)
*
|
1979-03-12 |
1987-03-31 |
Abbott Laboratories |
Glyceryl valproates
|
|
US4372960A
(en)
*
|
1980-12-12 |
1983-02-08 |
Warner-Lambert Company |
Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators
|
|
FR2515179A1
(fr)
*
|
1981-07-24 |
1983-04-29 |
Hoffmann La Roche |
Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique
|
|
IL67623A
(en)
*
|
1983-01-05 |
1984-09-30 |
Teva Pharma |
1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it
|
|
IL72381A
(en)
*
|
1983-07-20 |
1988-03-31 |
Sanofi Sa |
Pharmaceutical composition based on valproic acid
|
|
US4558070A
(en)
|
1983-10-26 |
1985-12-10 |
Abbott Laboratories |
Acid salts of valproic acid
|
|
GB8412358D0
(en)
|
1984-05-15 |
1984-06-20 |
Ucb Sa |
Pharmaceutical composition
|
|
GB8412357D0
(en)
*
|
1984-05-15 |
1984-06-20 |
Ucb Sa |
Pharmaceutical composition
|
|
US4668687A
(en)
*
|
1984-07-23 |
1987-05-26 |
Bristol-Myers Company |
Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
|
|
US4913906B1
(en)
|
1985-02-28 |
2000-06-06 |
Yissum Res Dev Co |
Controlled release dosage form of valproic acid
|
|
JPS6222785A
(ja)
*
|
1985-07-23 |
1987-01-30 |
Sanwa Kagaku Kenkyusho:Kk |
新規な２−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤
|
|
IT1190133B
(it)
*
|
1986-06-19 |
1988-02-10 |
Chiesi Farma Spa |
Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
|
|
DE3709230A1
(de)
*
|
1987-03-20 |
1988-10-06 |
Desitin Arzneimittel Gmbh |
Neues calciumsalz der valproinsaeure
|
|
JPS6422883A
(en)
*
|
1987-07-17 |
1989-01-25 |
Sanwa Kagaku Kenkyusho Co |
1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient
|
|
DE3773926D1
(de)
|
1987-07-22 |
1991-11-21 |
Farvalsa Ag |
Feuchtigkeitsstabile feste valproinsaeure-zubereitung und verfahren zu ihrer herstellung.
|
|
CA2007732A1
(en)
|
1989-01-17 |
1990-07-17 |
Gary L. Olson |
Cyclohexaneacetamide derivatives
|
|
FR2643556B1
(fr)
*
|
1989-02-27 |
1993-03-05 |
Sanofi Sa |
Composition pharmaceutique a liberation prolongee d'acide valproique
|
|
IT1231477B
(it)
*
|
1989-07-12 |
1991-12-07 |
Sigma Tau Ind Farmaceuti |
(pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
|
|
SK279285B6
(sk)
*
|
1991-05-02 |
1998-09-09 |
Daiichi Pharmaceutical Co. |
Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
|
|
US5439930A
(en)
*
|
1992-04-14 |
1995-08-08 |
Russian-American Institute For New Drug Development |
Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
|
|
US5440023A
(en)
*
|
1992-09-18 |
1995-08-08 |
Beckman Instruments, Inc. |
Method for making valproic acid derivatives
|
|
GB9319732D0
(en)
*
|
1993-09-24 |
1993-11-10 |
Ucb Sa |
Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
|
|
US5468733A
(en)
|
1993-09-30 |
1995-11-21 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
US5516759A
(en)
|
1994-12-08 |
1996-05-14 |
Tap Holdings Inc. |
LHRH antagonists having lactam groups at the N-terminus
|
|
IT1285801B1
(it)
*
|
1996-10-10 |
1998-06-24 |
Sigma Tau Ind Farmaceuti |
Procedimento migliorato per la preparazione dell'acido valproico
|
|
US6131106A
(en)
*
|
1998-01-30 |
2000-10-10 |
Sun Microsystems Inc |
System and method for floating-point computation for numbers in delimited floating point representation
|
|
US6620802B1
(en)
*
|
1999-11-23 |
2003-09-16 |
Corcept Therapeutics, Inc. |
Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
|
|
TWI238062B
(en)
|
1999-12-01 |
2005-08-21 |
Ucb Sa |
A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders
|
|
GB0004297D0
(en)
|
2000-02-23 |
2000-04-12 |
Ucb Sa |
2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
|
|
EP1356812B1
(en)
*
|
2000-12-28 |
2009-05-13 |
Hamilton Pharmaceuticals, Inc. |
Medicines for treatment and prevention of neurogenic pain
|
|
US6610326B2
(en)
|
2001-02-16 |
2003-08-26 |
Andrx Corporation |
Divalproex sodium tablets
|
|
EP1379236A4
(en)
*
|
2001-02-23 |
2009-01-21 |
Ucb Sa |
TREATMENT OF TICS, TREMOR AND RELATED DISORDER
|
|
WO2002094787A1
(en)
|
2001-05-23 |
2002-11-28 |
Ucb, S.A. |
2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
|
|
JP2005501108A
(ja)
*
|
2001-08-22 |
2005-01-13 |
第一製薬株式会社 |
神経変性治療におけるネフィラセタムの使用
|
|
AU2002335015B8
(en)
|
2001-10-16 |
2006-11-30 |
Memory Pharmaceuticals Corporation |
4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
|
|
US20040116506A1
(en)
*
|
2002-06-20 |
2004-06-17 |
Krusz John Claude |
Use of levetiracetam for treating or preventing acute headaches
|
|
US7557137B2
(en)
*
|
2002-08-05 |
2009-07-07 |
Bristol-Myers Squibb Company |
Gamma-lactams as beta-secretase inhibitors
|
|
US7090985B2
(en)
*
|
2002-12-03 |
2006-08-15 |
Ucb, S.A. |
Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
|
|
US20070135514A1
(en)
*
|
2002-12-03 |
2007-06-14 |
Berkley Lynch |
Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
|
|
ITMI20030573A1
(it)
*
|
2003-03-24 |
2004-09-25 |
Nikem Research Srl |
Composti ad azione nootropica, loro preparazione,
|
|
TW200508197A
(en)
|
2003-03-31 |
2005-03-01 |
Ucb Sa |
Indolone-acetamide derivatives, processes for preparing them and their uses
|
|
ES2323313T3
(es)
*
|
2003-12-02 |
2009-07-13 |
Ucb Pharma, S.A. |
Derivados de imidazol, procedimientos para prepararlos y sus usos.
|
|
US7618978B2
(en)
|
2004-04-22 |
2009-11-17 |
Eli Lilly And Company |
Amides as BACE inhibitors
|
|
EP1758855B1
(en)
|
2004-06-11 |
2007-11-21 |
UCB Pharma, S.A. |
Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
|
|
WO2006034196A1
(en)
*
|
2004-09-17 |
2006-03-30 |
Lifelike Biomatic Inc. |
Compositions for enhancing memory and methods therefor
|
|
MX2007009088A
(es)
*
|
2005-01-27 |
2007-09-13 |
Alembic Ltd |
Formulacion de liberacion extendida de levetiracetam.
|
|
US20070298098A1
(en)
*
|
2005-02-16 |
2007-12-27 |
Elan Pharma International Limited |
Controlled Release Compositions Comprising Levetiracetam
|
|
AU2006228947A1
(en)
*
|
2005-03-30 |
2006-10-05 |
Mylan Pharmaceuticals Ulc |
Combined-step process for pharmaceutical compositions
|
|
WO2006128693A2
(en)
|
2005-06-01 |
2006-12-07 |
Ucb Pharma, S.A. |
2 -oxo-i -pyrrolidine derivatives/ processes for preparing them and their therapeutic use on the central nervous system
|
|
EP1731149A1
(en)
*
|
2005-06-08 |
2006-12-13 |
Ucb S.A. |
Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
|
|
GB0517740D0
(en)
|
2005-08-31 |
2005-10-12 |
Novartis Ag |
Organic compounds
|
|
CA2631885A1
(en)
|
2005-12-07 |
2007-06-14 |
Ucb Pharma, S.A. |
Xanthine derivatives, processes for preparing them and their uses
|
|
AU2007223036A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
US20100216734A1
(en)
*
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
|
US7678808B2
(en)
*
|
2006-05-09 |
2010-03-16 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
|
US20080014264A1
(en)
*
|
2006-07-13 |
2008-01-17 |
Ucb, S.A. |
Novel pharmaceutical compositions comprising levetiracetam
|
|
EP2051696A2
(en)
*
|
2006-08-18 |
2009-04-29 |
Morton Grove Pharmaceuticals, Inc. |
Stable liquid levetiracetam compositions and methods
|
|
AU2007346591A1
(en)
*
|
2007-02-07 |
2008-08-14 |
Gosforth Centre (Holdings) Pty Ltd |
Treatment of ADHD
|
|
WO2008132142A2
(en)
|
2007-04-27 |
2008-11-06 |
Ucb Pharma S.A. |
New heterocyclic derivatives useful for the treatment of cns disorders
|
|
WO2009038412A2
(en)
|
2007-09-21 |
2009-03-26 |
Lg Life Sciences, Ltd. |
Beta-secretase inhibiting compounds
|
|
US20090176740A1
(en)
|
2007-11-30 |
2009-07-09 |
Phillips Ii Dauglas James |
Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
|
|
EP2273975B8
(en)
*
|
2008-03-03 |
2014-12-17 |
UCB Pharma, S.A. |
Pharmaceutical solutions, process of preparation and therapeutic uses
|
|
JP2010024156A
(ja)
|
2008-07-16 |
2010-02-04 |
Ucb Pharma Sa |
レベチラセタムを含む医薬組成物
|
|
JP2011529923A
(ja)
|
2008-08-06 |
2011-12-15 |
ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド |
精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法
|
|
BRPI0920342A2
(pt)
|
2008-10-16 |
2020-06-23 |
The Johns Hopkins University |
Uso de um inibidor da proteína vesicular sináptica 2a (sv2a) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica para melhora da função cognitiva, uso de levitiracetam ou um sal farmaceuticamente aceitável do mesmo, uso de brivaracetam ou um sal farmaceuticamente aceitável do mesmo, uso do seletracetam ou um sal farmaceuticamente aceitável do mesmo
|
|
US9125898B2
(en)
*
|
2008-11-14 |
2015-09-08 |
Neurotune Ag |
Acetam derivatives for pain relief
|
|
AU2009317280B2
(en)
|
2008-11-18 |
2014-03-06 |
Ucb Pharma, S.A. |
Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative
|
|
CA2747396C
(en)
|
2009-01-29 |
2015-12-08 |
Serge Cuypers |
Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
|
|
US8563036B2
(en)
|
2009-02-09 |
2013-10-22 |
Ucb Pharma, S.A. |
Pharmaceutical compositions comprising Brivaracetam
|
|
EP2461808A2
(en)
|
2009-08-07 |
2012-06-13 |
UCB Pharma S.A. |
Methods for enhancing the cognitive function
|